Posts tagged with ‘biotech’
Agricultural innovations through modern biotechnology have delivered significant economic, environmental, health and consumer benefits in recent years, but the full potential is even greater.
Crops yields must improve to feed a hungry planet amid global warming, but that will require more ecology-based farming and less biotechnology.
Biotechnology can help the poor, but whether it will depends on people of good will taking the time to understand and consider the arguments in some detail.
Last week, Jonathan Moreno called for international standards governing reproductive technologies. But if we want to ensure that frightening decisions about genetic modification are not being made around the world, we should first focus on developing strict regulatory standards here at home.
At the moment, the United States has no existing federal policies on a host [...]
The Pittsburgh Life Sciences Greenhouse was formed in 2000 as a focused incubator to provide capital investments and customized company formation. A focused incubator provides deep knowledge of global industry trends, national networks, and corporate collaborations to identify investment opportunities.
Refusing to pursue recent and possible future developments in medical research is itself a morally momentous decision—and that inaction has consequences Cohen and other right-wing thinkers refuse to acknowledge.
Americans know that the future fortunes of the country rest on scientific and technological advances, so Mr. President, let’s take biomedical science policy seriously.
Recent reports indicate that Europeans seem to be moving towards acceptance of genetically modified foods, as long as they are properly labeled. Conflict surrounds discussions on GM crops, but there are many facets of the debate over these seeds.
In a briefing yesterday for Capitol Hill staffers, neuroscientist Martha Farah explained that new technologies that enhance the power of the brain also raise questions about safety, economic fairness, privacy, and personal freedom.
Two stories this week describe two different approaches to plant genetic resources. Tuesday, researchers from Washington University and Iowa State university announced a completed draft of the corn genome. The same day, the Svalbard Global Seed Vault, which will store seeds from around the world in the event of catastrophic loss, opened on a remote Norwegian island.
The U.S. government has poured money into this experimental new vaccine alongside private investors. The effort just might carry the vaccine all the way to the marketplace.
AAAS president critiques U.S. science and tech policy; researchers map human impacts on ocean ecosystems; new materials for carbon capture; harnessing the tides and waves for energy; biodefense watchdog shuts down.
The National Research Council of the National Academies convened a symposium Wednesday to explore approaches among “Future Directions in Research at the Intersection of the Physical and Life Sciences.” The intersections up for discussion ranged across the research spectrum: from synthetic biology to geoengineering to bioterrorism.
NASA has a new face on the web; the NIH says gene therapy wasn’t the cause of death in a recent trial; open-source standards and net neutrality can improve global health; and more.
Researchers working independently in Japan and the U.S. published papers this week announcing the creation of non-embryonic pluripotent stem cells. The method side-steps the ethical concerns over the destruction of embryos and could open the doors for federal funding of research on stem cells and the medical breakthroughs they promise.
President Bush vetoed the Labor-HHS-Education appropriations bill, which would have increased funding for the National Institutes of Health from $29 billion to $30 billion and required open access to published NIH-funded research.
The drug maker agreed to pay $4.85 billion to settle lawsuits from individuals who say its painkiller Vioxx led to heart attacks and strokes. Predictions put the settlement costs at $25 billion when Vioxx was taken off the market in September 2004.
The J. Craig Venter Institute, along with researchers at MIT and the Center for Strategic and International Studies, recently released a report entitled “Synthetic Genomics | Options for Governance.” But are there larger unanswered questions about the societal impacts of creating synthetic life?
Two companies are about to become the first Embryonic Stem Cell biotech firms to draft FDA applications for human testing. For some time, ESC-research opponents have complained that human trials have involved therapies utilizing adult stem cells, but none have utilized embryonic stem cells.
